Clinical trials: Prostate Adenocarcinoma, open to volunteers
Prostate Cancer, Cancer of Prostate
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
Prostate Stereotactic ablative body radiotherapy (SABR) is an established technique that delivers radiation in a non-invasive approach for men with prostate cancer.
- Conditions
- Prostate Cancer, Cancer of Prostate, Prostate Adenocarcinoma
- Trial name
- iSMART (NCT05600400)
- Testing
- Stereotactic Ablative Body Radiation
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer, Adenocarcinoma
Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
To evaluate the role of biparametric MRI and image-fusion targeted biopsies for the detection of prostate cancer. To determine whether biparametric MRI (bpMRI) could be recommended as an alternative to multiparametric MRI (mpMRI)…
- Conditions
- Prostate Cancer, Adenocarcinoma, Prostatic Neoplasms, Prostatic Diseases
- Trial name
- IP7-PACIFIC (NCT05574647)
- Testing
- bpMRI, Image-Fusion targeted and systematic Biopsy
- Where
- 15 sites in United Kingdom
- Volunteers
- 3,600 people
- Sponsor
- Imperial College London
Breast Adenocarcinoma, Prostate Cancer (Adenocarcinoma)
Personalization of External Beam Radiation Therapy in Localised Tumours
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).
- Trial name
- MINIONS (NCT07047495)
- Testing
- prostate patient, breast patients
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones.
- Conditions
- Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease, Castration Resistant Metastatic Prostate Cancer, Radiotherapy
- Trial name
- OLYMPIAN (NCT07038304)
- Testing
- Metastasis directed radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer (Adenocarcinoma)
Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy
The investigators are interested here in the contribution of a new prostate cancer screening method and, more specifically, in the new and somewhat futuristic approach of artificial intelligence in the development of new, more…
- Trial name
- PROSTIA- BP (NCT06931496)
- Testing
- PROSTia test
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Central Hospital, Nancy, France
Colorectal Carcinoma, Rectal Prolapse
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic…
- Conditions
- Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer
- Trial name
- NCT06926374
- Testing
- Robotic surgery using the Sentire Surgical System
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer (Adenocarcinoma)
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy.
- Trial name
- PCS-XII (NCT06855589)
- Testing
- 6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
- Where
- 5 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Charles LeMoyne Hospital
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
Prostate Cancer (Adenocarcinoma), Renal Cancer
Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups.
- Trial name
- URO-ROBOT-2023 (NCT06844513)
- Testing
- Radical prostatectomy, Partial nephrectomy
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer (Adenocarcinoma)
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
This study aims to assess the impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on bone quality in patients with prostate cancer.
- Trial name
- NCT06838520
- Testing
- Bone health assessment
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Prostate Cancer (Adenocarcinoma)
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods.
- Trial name
- NCT06820333
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Radiotherapy Induced Diarrhea, Acute Radiation Enteritis
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation.
- Conditions
- Radiotherapy Induced Diarrhea, Acute Radiation Enteritis, Prostate Cancer, Cervical Adenocarcinoma
- Trial name
- NCT06783153
- Testing
- Rifaximin 550 MG, Standard Care Chemoradiation
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Prostate Cancer (Adenocarcinoma)
Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions
The goal of this observational study is to assess the chance to predict prostate cancer with the analysis of specific values found in images obtained from RMmp (multiparametric magnetic resonance imaging) of patients who went…
- Trial name
- NCT06774781
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Adenocarcinoma
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utilize Fluorine 18 or Gallium 68 as the positron emitter for PET imaging.
- Trial name
- NCT06736054
- Testing
- Copper 61-PSMA PET/CT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Prostate Cancer (Adenocarcinoma)
Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day.
- Trial name
- NCT06665932
- Testing
- Stereotactic radiotherapy
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Ostrava
Prostate Cancer, Prostate Adenocarcinoma
Customized TULSA-PRO Ablation Registry
This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
- Trial name
- CARE (NCT05001477)
- Testing
- TULSA Procedure
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Profound Medical Inc.
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Prostate Cancer, Prostate Adenocarcinoma
Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer
The goal of this clinical trial is to assess the non-inferiority irradiating low and intermediate risk, localized prostate cancer in two fractions of radiotherapy, compared to five fractions of radiotherapy which is the standard…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Trial name
- TURBO (NCT06518226)
- Testing
- Ultrahypofractionated MRgRT in 2 fractions, Standard of care: MRgRT in 5 fractions
- Where
- Netherlands
- Volunteers
- 160 people
- Sponsor
- UMC Utrecht
Prostate Cancer, Adenocarcinoma of the Prostate
Prospective Prostate Cancer and Patient-reported Outcomes Registry
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or…
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Locally Advanced Prostate Carcinoma, Locally Advanced Prostate Adenocarcinoma
- Trial name
- Prosquare (NCT04694924)
- Testing
- standard of care
- Where
- 4 sites in Belgium
- Volunteers
- 5,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven